Predicting relapse in children diagnosed with acute lymphoblastic leukemia
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia
This study is looking to help doctors better predict if children with acute lymphoblastic leukemia might have a relapse by finding certain cells in their blood right at the time of diagnosis, so they can adjust treatments and improve outcomes for these kids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11047678 on NIH RePORTER |
What this research studies
This research focuses on improving the prediction of relapse in children diagnosed with acute lymphoblastic leukemia (ALL). By utilizing a cutting-edge single-cell proteomic approach, the study aims to identify specific pre-B cells that indicate a higher risk of relapse at the time of diagnosis. This method is designed to provide immediate and actionable insights, allowing for timely adjustments in treatment strategies. The goal is to enhance the accuracy of relapse predictions and ultimately reduce the incidence of relapse in affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who have been newly diagnosed with acute lymphoblastic leukemia.
Not a fit: Patients who are older than 11 years or those with other types of leukemia may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates for children with acute lymphoblastic leukemia by enabling earlier and more effective interventions.
How similar studies have performed: This approach is innovative and has shown promise in preliminary findings, indicating a potential breakthrough in relapse prediction for acute lymphoblastic leukemia.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Davis, Kara Lynn — Stanford University
- Study coordinator: Davis, Kara Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.